Ascendis Pharma A/S (ASND) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Which has more risk and volatility, TAK or ASND?

Takeda Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Which has better earnings & valuation, TAK or ASND?

Takeda Pharmaceutical has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$30.09B	1.59	$712.33M	$0.30	50.27
Ascendis Pharma A/S	$490.75M	23.74	-$409.12M	-$5.16	-36.89

Does the media refer more to TAK or ASND?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 10 mentions for Takeda Pharmaceutical. Ascendis Pharma A/S's average media sentiment score of 1.37 beat Takeda Pharmaceutical's score of 0.76 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate TAK or ASND?

Ascendis Pharma A/S has a consensus target price of $243.36, suggesting a potential upside of 27.83%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders have more ownership in TAK or ASND?

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is TAK or ASND more profitable?

Takeda Pharmaceutical has a net margin of 3.20% compared to Ascendis Pharma A/S's net margin of -54.94%. Takeda Pharmaceutical's return on equity of 10.50% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.20%	10.50%	5.10%
Ascendis Pharma A/S	-54.94%	N/A	-24.31%

Summary

Takeda Pharmaceutical and Ascendis Pharma A/S tied by winning 8 of the 16 factors compared between the two stocks.